AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15356671 — intervention group
Group type: COMPARATOR
Intervention: 10% of energy from grape juice
Number of subjects: 40
Study 11254918 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 169
Study 11254918 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg
Number of subjects: 169
Study 11254918 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 80 mg
Number of subjects: 169
Study 11254918 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 169
Study 11254918 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 169
Study 11254918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 9511827 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody response against alpha‐toxin
Number of subjects: 63
Study 9511827 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody response against teichoic acid
Number of subjects: 63
Study 9511827 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive antibody response to at least one of the three antigens
Number of subjects: 63
Study 9511827 — intervention group
Group type: EXPERIMENTAL
Intervention: Complicated septicaemia (alpha-toxin response)
Number of subjects: 63
Study 9511827 — intervention group
Group type: COMPARATOR
Intervention: Uncomplicated septicaemia (alpha-toxin response)
Number of subjects: 63
Study 9511827 — intervention group
Group type: EXPERIMENTAL
Intervention: Complicated septicaemia (teichoic acid response)
Number of subjects: 63
Study 9511827 — intervention group
Group type: COMPARATOR
Intervention: Uncomplicated septicaemia (teichoic acid response)
Number of subjects: 63
Study 9511827 — intervention group
Group type: EXPERIMENTAL
Intervention: Complicated septicaemia (lipase response)
Number of subjects: 63
Study 9511827 — intervention group
Group type: COMPARATOR
Intervention: Uncomplicated septicaemia (lipase response)
Number of subjects: 63
Study 9511827 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial antibody levels
Number of subjects: 63
Study 9511827 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA titres against alpha‐toxin
Number of subjects: 63
Study 7798807 — intervention group
Group type: EXPERIMENTAL
Intervention: Nailfold capillaroscopy with discriminant analysis
Number of subjects: 307
Study 7798807 — intervention group
Group type: EXPERIMENTAL
Intervention: Nailfold capillaroscopy
Number of subjects: 307
Study 3366055 — intervention group
Group type: EXPERIMENTAL
Intervention: Different reinforcement conditions during drinking sessions
Number of subjects: 0
Study 3366055 — intervention group
Group type: EXPERIMENTAL
Intervention: Group that acquired tolerance most rapidly
Number of subjects: 0
Study 30504318 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 0
Study 30504318 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax and Rituximab
Number of subjects: 0
Study 30504318 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax
Number of subjects: 0
Study 30504318 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapies
Number of subjects: 0
Study 26311397 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal writing condition (pencil with polystyrene)
Number of subjects: 51
Study 26311397 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired writing condition (pencil with steel)
Number of subjects: 51
Study 26311397 — intervention group
Group type: COMPARATOR
Intervention: Pointing condition (control)
Number of subjects: 51
Study 24667662 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-day regimen of dihydroartemisinin-piperaquine (total dose 360 mg dihydroartemisinin and 2880 mg piperaquine)
Number of subjects: 80
Study 24667662 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-day regimen of dihydroartemisinin-piperaquine (total dose 360 mg dihydroartemisinin and 2880 mg piperaquine)
Number of subjects: 80
Study 24667662 — intervention group
Group type: COMPARATOR
Intervention: Both regimens (two-day and three-day)
Number of subjects: 80
Study 22475524 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 22475524 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study 20636866 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical agents (specific agents not mentioned)
Number of subjects: 0
Study 20636866 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment (control)
Number of subjects: 0
Study 16900483 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans-retinoic acid (ATRA) at 90 mg/m2/day in three divided doses for 3 consecutive days per week, combined with interferon-α2a (IFN-α2a) at 3 × 106 U/m2/day subcutaneously for 5 consecutive days per week in 4 week cycles.
Number of subjects: 32
Study 16900483 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified; no active control reported.
Number of subjects: 32
Study 16212835 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD subtypes (severe combined and talkative)
Number of subjects: 1610
Study 16212835 — intervention group
Group type: COMPARATOR
Intervention: Population prevalence of broadly defined mania
Number of subjects: 1610
Study 16212835 — intervention group
Group type: EXPERIMENTAL
Intervention: Children and adolescents with ADHD
Number of subjects: 1610
Study 12133654 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 microg/kg ivermectin every 3 months
Number of subjects: 657
Study 12133654 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 then 800 microg/kg ivermectin every 3 months
Number of subjects: 657
Study 12133654 — intervention group
Group type: COMPARATOR
Intervention: 150 microg/kg ivermectin yearly (reference group)
Number of subjects: 657
Study 8842905 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative intravenous ketorolac
Number of subjects: 34
Study 8842905 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient controlled analgesia with morphine (0.015 mg/kg)
Number of subjects: 34
Study 8842905 — intervention group
Group type: COMPARATOR
Intervention: No ketorolac
Number of subjects: 34
Study 8842905 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulation on the first postoperative day
Number of subjects: 34
Study 8842905 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge within 2 days of surgery
Number of subjects: 34
Study 8842905 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term donor site morbidity
Number of subjects: 34
Study 2180549 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin-tetrapeptide (CCK-4)
Number of subjects: 11
Study 2180549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 6927982 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium glycerophosphate (experimental groups)
Number of subjects: 0
Study 6927982 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 31226322 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 10mg twice daily for 7 days starting 21 days after IUS insertion
Number of subjects: 42
Study 31226322 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily for 7 days starting 21 days after IUS insertion
Number of subjects: 42
Study 31226322 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 42
Study 31226322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 29150087 — intervention group
Group type: EXPERIMENTAL
Intervention: DAM (dexmedetomidine, methadone, alfaxalone)
Number of subjects: 44
Study 29150087 — intervention group
Group type: COMPARATOR
Intervention: DKM (dexmedetomidine, methadone, ketamine)
Number of subjects: 44
Study 29150087 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study 25545543 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-frequency bioelectrical impedance analysis (SF-BIA)
Number of subjects: 41
Study 25545543 — intervention group
Group type: COMPARATOR
Intervention: Bioelectrical impedance spectroscopy (BIS)
Number of subjects: 41
Study 23433769 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD9668 60 mg twice daily for 4 weeks
Number of subjects: 38
Study 23433769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 21334098 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg of daily oral dexamethasone for 2 days
Number of subjects: 200
Study 21334098 — intervention group
Group type: COMPARATOR
Intervention: 50 mg of daily oral prednisone for 5 days
Number of subjects: 200
Study 19962101 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil lavandin (standard care plus essential oil lavandin)
Number of subjects: 150
Study 19962101 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 150
Study 19962101 — intervention group
Group type: COMPARATOR
Intervention: Sham (standard care plus jojoba oil)
Number of subjects: 150
Study 17683960 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid Endarterectomy (CEA)
Number of subjects: 2972
Study 17683960 — intervention group
Group type: COMPARATOR
Intervention: Carotid Angioplasty with or without Stent placement (CAS)
Number of subjects: 2972
Study 15566514 — intervention group
Group type: EXPERIMENTAL
Intervention: TAE combined with PEIT
Number of subjects: 42
Study 15566514 — intervention group
Group type: EXPERIMENTAL
Intervention: TAE combined with RFA
Number of subjects: 42
Study 15566514 — intervention group
Group type: COMPARATOR
Intervention: PTA only (PEIT, 14; RFA, 6)
Number of subjects: 42
Study 15566514 — intervention group
Group type: COMPARATOR
Intervention: Overall recurrence
Number of subjects: 42
Study 15566514 — intervention group
Group type: COMPARATOR
Intervention: Prior TAE
Number of subjects: 42
Study 11210248 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser irradiation with lower total delivered energy (under 30 J)
Number of subjects: 150
Study 11210248 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser irradiation with higher energy settings
Number of subjects: 150
Study 11210248 — intervention group
Group type: COMPARATOR
Intervention: Non-irradiated samples
Number of subjects: 150
Study 10468681 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid solution (200 mL, 75 mg of 13C-urea)
Number of subjects: 50
Study 10468681 — intervention group
Group type: COMPARATOR
Intervention: Orange juice (200 mL, 75 mg of 13C-urea)
Number of subjects: 50
Study 10468681 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid solution (200 mL, 50 mg of 13C-sodium acetate)
Number of subjects: 50
Study 10468681 — intervention group
Group type: COMPARATOR
Intervention: Orange juice (200 mL, 50 mg of 13C-sodium acetate)
Number of subjects: 50
Study 7711762 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomechanical Ankle Platform System (BAPS) training
Number of subjects: 28
Study 7711762 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 2676492 — intervention group
Group type: EXPERIMENTAL
Intervention: Water jet (WJ) laser
Number of subjects: 57
Study 2676492 — intervention group
Group type: COMPARATOR
Intervention: Non-contact (NC) modality
Number of subjects: 57
Study 65728 — intervention group
Group type: EXPERIMENTAL
Intervention: CVP (cyclophosphamide, vincristine, and prednisone)
Number of subjects: 62
Study 65728 — intervention group
Group type: COMPARATOR
Intervention: ABP (adriamycin, bleomycin, and prednisone)
Number of subjects: 62
Study 65728 — intervention group
Group type: EXPERIMENTAL
Intervention: CVP (after cross-over)
Number of subjects: 62
Study 65728 — intervention group
Group type: COMPARATOR
Intervention: ABP (after cross-over)
Number of subjects: 62
Study 31807750 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 19114
Study 31807750 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated hypertension
Number of subjects: 19114
Study 31807750 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors related to treated but uncontrolled BP
Number of subjects: 19114
Study 31201226 — intervention group
Group type: EXPERIMENTAL
Intervention: Video decision support tool
Number of subjects: 252
Study 28166797 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal (HFAT; 50% fat)
Number of subjects: 40
Study 28166797 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate meal (HCHO; 70% carbohydrate)
Number of subjects: 40
Study 28166797 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual physical activity (HiPA)
Number of subjects: 40
Study 28166797 — intervention group
Group type: COMPARATOR
Intervention: Habitual physical activity (LoPA)
Number of subjects: 40
Study 25548849 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of botulinum toxin A (BoNT A) after ablative fractional CO2 laser treatment
Number of subjects: 10
Study 25548849 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control) after ablative fractional CO2 laser treatment
Number of subjects: 10
Study 22993168 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline tartrate plus Quitline‐counselling
Number of subjects: 392
Study 22993168 — intervention group
Group type: COMPARATOR
Intervention: Quitline‐counselling alone
Number of subjects: 392
Study 20929989 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for inducible ischemia
Number of subjects: 1123
Study 20929989 — intervention group
Group type: COMPARATOR
Intervention: No screening for inducible ischemia
Number of subjects: 1123
Study 20929989 — intervention group
Group type: EXPERIMENTAL
Intervention: UK Prospective Diabetes Study (UKPDS) risk engine
Number of subjects: 1123
Study 20635764 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 0
Study 16706244 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 1% gel (once-daily application)
Number of subjects: 160
Study 16706244 — intervention group
Group type: COMPARATOR
Intervention: Azelaic acid 15% gel (twice-daily application)
Number of subjects: 160
Study 14767168 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride gel
Number of subjects: 773
Study 14767168 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 773
Study 11713157 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotinine-feedback, behaviorally based education intervention (n = 51)
Number of subjects: 87
Study 11713157 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotinine-feedback, behaviorally based education intervention (n = 60)
Number of subjects: 87
Study 9325559 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine treatment
Number of subjects: 10
Study 9325559 — intervention group
Group type: COMPARATOR
Intervention: Ketamine infusion (placebo-controlled)
Number of subjects: 10
Study 7496554 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen up to 4 g/d
Number of subjects: 0
Study 7496554 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs (initially in lower analgesic doses)
Number of subjects: 0
Study 7496554 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacologic measures
Number of subjects: 0
Study 2499187 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms of misoprostol QID
Number of subjects: 120
Study 2499187 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms of misoprostol QID
Number of subjects: 120
Study 2499187 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms of misoprostol QID
Number of subjects: 120
Study 2499187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 30130627 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin (2.5 mg immediate release)
Number of subjects: 72
Study 30130627 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin (10 mg extended release)
Number of subjects: 72
Study 27692906 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy (SG)
Number of subjects: 72
Study 27692906 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y Gastric Bypass (RYGB)
Number of subjects: 72
Study 26004888 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose selenium supplementation (Se+, n = 75)
Number of subjects: 150
Study 26004888 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose selenium supplementation (Se-, n = 75)
Number of subjects: 150
Study 26004888 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose selenium supplementation (Se+, n = 75) in SIRS patients
Number of subjects: 150
Study 26004888 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose selenium supplementation (Se-, n = 75) in SIRS patients
Number of subjects: 150
Study 26004888 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose selenium supplementation (Se+, n = 75) in sepsis patients
Number of subjects: 150
Study 26004888 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose selenium supplementation (Se-, n = 75) in sepsis patients
Number of subjects: 150
Study 22817768 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of lorazepam (LZ)
Number of subjects: 20
Study 22817768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21705404 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mM yohimbine plus 1 mM propranolol (intervention)
Number of subjects: 12
Study 21705404 — intervention group
Group type: COMPARATOR
Intervention: 1 mM propranolol (control)
Number of subjects: 12
Study 19105405 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with coaxil
Number of subjects: 86
Study 19105405 — intervention group
Group type: COMPARATOR
Intervention: Somatotropic monotherapy
Number of subjects: 86
Study 16803842 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy (PMRT)
Number of subjects: 1951
Study 15461995 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant training (CST)
Number of subjects: 10
Study 15461995 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training (SWEET)
Number of subjects: 10
Study 15461995 — intervention group
Group type: COMPARATOR
Intervention: Control values
Number of subjects: 10
Study 15461995 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-exercise recovery
Number of subjects: 10
Study 10987525 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve conduction velocity test
Number of subjects: 79
Study 10987525 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure‐Specified Sensory Device
Number of subjects: 79
Study 9202963 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser trabeculoplasty (ALT)
Number of subjects: 39
Study 9202963 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium eye drops
Number of subjects: 39
Study 9202963 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 39
Study 8307772 — intervention group
Group type: EXPERIMENTAL
Intervention: Video with information and skills training (experimental)
Number of subjects: 69
Study 8307772 — intervention group
Group type: COMPARATOR
Intervention: Video with information only (control)
Number of subjects: 69
Study 2886821 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin
Number of subjects: 565
Study 2886821 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide and cisplatin (CP)
Number of subjects: 565
Study 2886821 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, doxorubicin, and cisplatin (CAP)
Number of subjects: 565
Study 30535269 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive counseling program (seven telephone sessions)
Number of subjects: 1604
Study 30535269 — intervention group
Group type: COMPARATOR
Intervention: Quitline referral (1-2 telephone counseling sessions)
Number of subjects: 1604
Study 29290126 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotora intervention
Number of subjects: 0
Study 29290126 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention
Number of subjects: 0
Study 29290126 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotora and video interventions
Number of subjects: 0
Study 29290126 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonintervention)
Number of subjects: 0
Study 29290126 — intervention group
Group type: EXPERIMENTAL
Intervention: Group video sessions
Number of subjects: 0
Study 29290126 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual video sessions with video and promotora
Number of subjects: 0
Study 29030329 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to the colorectal cancer module of the German DIPEx website for 2 weeks
Number of subjects: 212
Study 29030329 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 212
Study 23919667 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforming methacrylate dressing (TMD)
Number of subjects: 19
Study 23919667 — intervention group
Group type: COMPARATOR
Intervention: Silver-containing carboxymethylcellulose dressing (CMC-Ag)
Number of subjects: 19
Study 23927320 — intervention group
Group type: EXPERIMENTAL
Intervention: DCE-CT QA protocol with dynamic flow imaging phantom
Number of subjects: 3
Study 23927320 — intervention group
Group type: EXPERIMENTAL
Intervention: ASIR reconstruction process
Number of subjects: 3
Study 23927320 — intervention group
Group type: EXPERIMENTAL
Intervention: Vendor specific modes (e.g., axial shuttle)
Number of subjects: 3
Study 23927320 — intervention group
Group type: EXPERIMENTAL
Intervention: DCE-CT QA protocol
Number of subjects: 3
Study 21529740 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg 12 hours before intervention with another 40 mg preprocedure dose, n = 120)
Number of subjects: 241
Study 21529740 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg 12 hours before intervention with another 40 mg preprocedure dose)
Number of subjects: 241
Study 21529740 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 121)
Number of subjects: 241
Study 18971603 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic shock waveform (Bi), energies used: 100-150-200-300-360 J
Number of subjects: 224
Study 18971603 — intervention group
Group type: COMPARATOR
Intervention: Monophasic shock waveform (Mo), energies used: 100-200-300-360 J
Number of subjects: 224
Study 18971603 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Bi and Mo)
Number of subjects: 224
Study 16522927 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental partially hydrolyzed rice protein-based formula (RPF)
Number of subjects: 65
Study 16522927 — intervention group
Group type: COMPARATOR
Intervention: Standard intact cow's milk protein-based formula (CMF)
Number of subjects: 65